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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S291increase in IL1ra. This was especially seen in the M2 macrophages,
indicating that OA SF enhances this phenotype. Surprisingly, RA SF also
seemed to decrease pro-inﬂammatory processes as shown by a
decrease of IL10 and an increase of IL1ra, but also by the decrease of IL6.
In conclusion, SF from diseased joints does not induce pro-inﬂamma-
tory processes, even not when from RA joints. Based on our results, SF
from diseased joints might even induce anti-inﬂammatory processes.
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SYNOVIOCYTE INFLAMMATORY RESPONSES TO CALCIUM
PYROPHOSPHATE DIHYDRATE CRYSTALS INVOLVES CD14 AND TLR-4.
C.R. Scanzello y, A. Nair z, A. Margolis z, K. Mikecz z, A. Finnegan z. yUniv.
of Pennsylvania, Philadelphia, PA, USA; zRush Univ. Med. Ctr., Chicago, IL,
USA
Purpose: Low-grade synovial inﬂammation is seen in the setting of
osteoarthritis (OA), even in early-stages, although the molecular trig-
gers of inﬂammation in OA are as yet unclear. Stimulation of Toll-like
receptors (TLRs) by endogenous molecules released during cartilage
matrix damage and chondrocyte stress is hypothesized to be one
mechanism leading to synovial inﬂammation in OA. We previously
reported that a TLR co-receptor, soluble CD14 (sCD14), is found in
synovial ﬂuid (SF) from patients with early and advanced stage OA, and
can augment responses of ﬁbroblast-like synoviocytes (FLS) to typical
TLR-2 and TLR-4 ligands. The purpose of the current study was to
determine if sCD14 can impact FLS responses to crystalline ligands
(speciﬁcally MSU and CPPD) that have relevance to OA pathogenesis.
Methods: Synovial tissue specimens for establishment of FLS lines were
obtained from asymptomatic organ donors with no documented his-
tory of joint disease via IRB approved protocols. Recombinant human
CD14 (0.5 ug /ml, based on concentrations found in patient SF) in
combination with MSU crystals or CCPD crystals (both from Invivogen)
used in concentrations from 0.05 to 50 ug/ml were used to stimulate
primary FLS at passage 4. Stimulationwas measured by IL-8 release into
the culture media measured by ELISA (Invitrogen). Responses of HEK-
293 cell lines transfected with TLR-2 or TLR-4 were measured to
determine the dependence of observed responses on these receptors. A
peptide inhibitor of TLR-4 signaling (CLI-095, Invivogen) was used to
test whether FLS responses were related to TLR-4 mediated mediated
signaling.
Results: CPPD, but not MSU, was able to stimulate IL-8 production from
FLS cells in the presence of CD14. Experiments in three separate cell
lines demonstrated that addition of CD14 augmented the effect of CPPD
down to a concentration of 0.5 ug/ml (repeated measures ANOVA, p ¼
0.02 at 0.5 ug/ml, with CD14 vs. without CD14). CPPD, in combination
with rhCD14, was able to stimulate HEK-293 cells transfected with TLR-
4, but not TLR-2. In FLS cells, addition of the TLR-4 inhibitor CLI-095
prevented the response to CD14þCPPD.
Conclusions: CPPD crystals stimulate FLS production of IL-8 in the
presence of CD14. Our experiments indicate that TLR-4 is involved in
this response. As CPPD crystals are known to be common in the joint
tissues and ﬂuid of patients affected by OA, it is possible that the
synovial response to these crystals may contribute to inﬂammation in
OA.
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ANTI-INFLAMMATORY EFFECTS OF LANSOPRAZOLE BY INHIBITING
NITRIC OXIDE PRODUCTION VIA REACTIVE OXYGEN SPECIES IN
MURINE MACROPHAGE RAW 264.7 CELLS
S. Ichimaru, S. Nakagawa, Y. Arai, S. Tsuchida, H. Inoue, T. Matsuki,
D. Taniguchi, R. Oda, H. Fujiwara, T. Kubo. Kyoto Prefectural Univ. of Med.,
Kyoto, Japan
Purpose: Lansoprazole (LPZ), proton pump inhibitor, is widely used
clinically to treat gastrointestinal mucosal disorders. The mucosal-
protective effects of PPIs are due primarily to their inhibition of P-
ATPase. More recently, however, PPIs were shown to have local
pleiotropic effects in the gastric mucosa, including having anti-
apoptotic effects, inhibiting the generation of reactive oxygen species
(ROS), and inhibiting the expression of macrophage adhesion mole-
cules. Aberrantly activated macrophages overproduce inﬂammatorymediators such as nitric oxide (NO) and prostaglandin E2 (PGE2),
both of which are involved in the pathogenesis of many inﬂamma-
tory diseases including rheumatoid arthritis. Agents that target
macrophages, inhibiting the secretion of multiple inﬂammatory
mediators, may provide a breakthrough as novel therapy for patients
with inﬂammatory disorders. The purpose of this study is to inves-
tigate the effects of LPZ on activated macrophages and the mecha-
nisms by which LPZ inhibits the production of inﬂammatory
mediators such as NO and PGE2.
Methods: RAW264.7 murine macrophages were used in this study. The
cells were incubated with various concentrations of LPZ for 24 h and the
cell viability was evaluated by MTS assay. The cells were treated with
various concentrations of LPZ in the presence or absence of lip-
opolysaccharide (LPS), and the concentration of NO and PGE2 in
supernatant was measured. iNOS and COX-2 expression were analysed
by Western blotting. We used RT-PCR to determine whether P-ATPase
mRNA is expressed in RAW264.7 cells. We measured intracellular ROS
concentrations of LPS-stimulated cells by ﬂow cytometry in the pres-
ence or absence of 100mM LPZ. To determine whether LPS-induced ROS
affects NO and PGE2 production, we measured NO and PGE2 levels after
controlling ROS levels using antioxidants such as N-acetyl-L-cysteine
(NAC), an ROS scavenger, and Diphenylene iodonium (DPI), an inhibitor
of NADPH oxidase.
Results: LPZ, at concentrations of 0–100 mM, had no effects on the
viability of RAW264.7 cells. LPZ inhibited the LPS-induced production of
NO and PGE2 in a concentration-dependent manner. The expression of
iNOS and COX-2 was also suppressed by LPZ at a concentration of 100
mM. P-ATPase expressed in mouse gastric mucosal tissue but not in
RAW264.7 cells. In addition, LPZ alone did not alter ROS levels in the
absence of LPS, whereas preincubationwith LPZ prior to LPS stimulation
signiﬁcantly reduced the levels of ROS. NAC had no effect on NO levels
and, DPI, an inhibitor of NADPH oxidase, decreased NO levels, but nei-
ther NAC nor DPI altered PGE2 levels.
Conclusions: We found that LPZ not only inhibited NO and PGE2
production but also suppressed iNOS and COX-2 expression. This
result suggests that LPZ exerts anti-inﬂammatory effects by sup-
pressing the expression of iNOS and COX-2. We found that LPS
stimulation increased the production of both ROS and NO and that
DPI suppresses LPS-induced NO production. These ﬁndings suggest
that, LPS stimulation increases ROS production and is associated
with inﬂammatory responses by inducing NO production. NAC did
not inhibit LPS-induced NO production, indicating that once ROS has
been produced, it is difﬁcult to control NO production. Our ﬁndings,
showing that LPZ suppressed the inﬂammatory activity of activated
macrophages in vitro, suggest that LPZ may be promising in the
treatment of inﬂammatory diseases involving activated macrophages
including rheumatoid arthritis. Studies in animal models may show
these therapeutic effects.
Table. Markers of atherosclerosis in relation to prevalent knee OA, stratiﬁed by
gender
Knee OA (Women) OR (95% CI)* Knee OA (Men) OR (95% CI)*
Coronary artery
calciﬁcation
1.11 (0.95–1.30) 1.11 (0.86–1.43)
CD40L 1.32 (1.12–1.56)** 1.05 (0.80–1.37)
VCAM-1 1.31 (1.08–1.59)** 1.08 (0.82–1.42)
VEG-f 1.08 (0.93–1.24) 1.07 (0.90–1.28)
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MARKERS OF ATHEROSCLEROSIS IN RELATION TO PRESENCE AND
PROGRESSION OF KNEE OSTEOARTHRITIS: THE ROTTERDAM STUDY
T.A. Hoeven, M. Kavousi, M.A. Ikram, J.B. van Meurs, P.J. Bindels,
A. Hofman, O.H. Franco, S.M. Bierma-Zeinstra. Erasmus Univ. Med. Ctr.,
Rotterdam, Netherlands
Purpose: Several observational studies have found an association
between subclinical measures of atherosclerosis and osteoarthritis
(OA) of the hands and knees, predominantly among women. Dif-
ferent mechanisms have been suggested to explain the potential
relation between atherosclerosis and OA; systemic low-grade
inﬂammation caused by visceral adipose tissue is particularly men-
tioned and may consequently highlight a route to improve pre-
vention and treatment of atherosclerosis and OA. However, the
reported associations between subclinical measures of athero-
sclerosis and OA were modest in effect size, derived mainly from
cross-sectional studies and generally attenuated after adjustment for
cardiovascular risk factors. Furthermore, previous results were
inconsistent for the different imaging markers of atherosclerosis. In
previous work, we found no relation between peripheral measure-
ments of atherosclerosis (including carotid intima-media-thickness
or carotid plaque) and progression of knee, hand, or hip OA in a
large sample of a prospective cohort study. Hence, it remains unclear
whether atherosclerosis and OA are related or whether they aresimply independent disorders with shared risk factors. Coronary
artery calciﬁcation (CAC) is considered a late stage pathognomonic
feature of coronary atherosclerosis. CD40L, VCAM-1, and VEG-f are
serum biomarkers that reﬂect initial inﬂammatory stages of vascular
wall damage in the ischemic cascade. In the vascular endothelium,
VEG-f is a protein that stimulates angiogenesis, CD-40L and VCAM-1
are molecules that initiate coagulation and immune responses. We
therefore investigated the association between these markers of
early and late atherosclerosis and presence and progression of knee
OA, a possible cardiometabolic phenotype of OA, in a large pop-
ulation-based cohort study.
Methods: The analyses on prevalence of knee OA were performed in
3,465 participants from the prospective population-based Rotterdam
Study (mean age 73.1 years, 61% women). Data on coronary artery
calciﬁcation (CAC) were available for 1,669 participants and plasma
levels of CD40L, VCAM-1, and VEG-f in 975. For the analyses on
progression of knee OA, data on CAC was available for 979 partic-
ipants (17% progressors), and 246 participants (20% progressors) had
plasma levels of CD40L, VCAM-1, and VEG-f. We scored radiographs
of the knee with the Kellgren-Lawrence (K&L) score for osteoarthritis
(knee OA present with a K&L graded score greater or equal to 2) at
baseline and follow-up (average follow-up time 4.5 years (0.5)).
Overall progression of knee OA was deﬁned as the combination of
the incidence and the progression of existing OA at baseline and was
considered present if the K&L score increased 1 grade between
baseline and follow-up visit. After stratiﬁcation by gender, multi-
variate logistic regression models with generalized estimated equa-
tions on knee level were used to calculate odds ratios (95%
conﬁdence intervals) for prevalence and progression of knee OA per
each SD increase in marker levels.
Results: Within the study population, 18% had radiographic knee OA,
11% of the men, 23% of the women. CAC and VEG-f were not associated
with prevalent knee OA. Among women, CD40L (adjusted odds ratio
(aOR) 1.31 (1.12 to 1.56)) and VCAM-1 (aOR 1.31 (1.08 to 1.59)) were
associated with prevalent knee OA (table). No associations with pro-
gression were found in women. In men, too few progressors were
available to assess associations.Conclusions: In this population-based study, coronary artery calciﬁ-
cation and VEG-f were not associated with presence or progression of
knee OA. However, plasma levels of CD40L and VCAM-1 were higher in
women with knee OA and not in men. This might reﬂect an association
between early atherosclerosis and knee OA through low-grade systemic
inﬂammation in women.
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MECHANISMS INVOLVED IN INHIBITION OF INFLAMMATION IN
THP-1 CELLS BY THE HEXADECYLAMIDE DERIVATIVE OF
HYALURONIC ACID.
F. Oliviero y, A. Scanu y, R. Ramonda y, P. Frallonardo y, P. Sfriso y,
J. Dayer z, L. Punzi y. yRheumatology Unit, Univ. of Padova, Padova, Italy;
z Faculty of Med., Geneva, Switzerland
Purpose: Intra-articular injections of hyaluronic acid are widely used in
the treatment of inﬂammatory and degenerative joint diseases. The
immune regulation exerted by hyaluronic acid is modulated by its
interaction with different receptors including CD44 and the toll-like
receptors 2 and 4. A novel hexadecylamide derivative of hyaluronic acid
(HA), HYADD4, has recently been tested in animal models of osteo-
arthritis, showing both anti-inﬂammatory and anabolic effects. The
purpose of this study is to investigate the possiblemechanisms involved
on the effect of unmodiﬁed and hexadecylamide derivative
